Page last updated: 2024-11-07

u 74500a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

U 74500A: potent inhibitor of iron-dependent lipid peroxidation; has excellent activity in in vivo models of experimental CNS trauma & ischemia; structure given in first source; RN given is for 3,6-bis(diethylamino) cpd; Cancer Lett 1992;64(1):61-6 uses 5,6-bis(diethylamino) cpd for U 74500A [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID107964
MeSH IDM0151131

Synonyms (14)

Synonym
pregna-1,4,9(11)-triene-3,20-dione, 21-(4-(3,6-bis(diethylamino)-2-pyridinyl)-1-piperazinyl)-16-methyl-, hydrochloride, (16alpha)-
21-(4-(3,6-bis(diethylamino)-2-pyridinyl)-1-piperazinyl)-16-methylpregna-1,4,9(11)triene-3,20-dione hcl
u-74500a
u 74500a
21-(4-(5,6-bis(diethylamino)-2-pyridinyl)-1-piperazinyl)-16-methylpregna-1,4,9(11)triene-3,20-dione hcl
u74500a
unii-idw4rcm01l
110101-65-0
idw4rcm01l ,
pregna-1,4,9(11)-triene-3,20-dione, 21-(4-(3,6-bis(diethylamino)-2-pyridinyl)-1-piperazinyl)-16-methyl-, hydrochloride, (16.alpha.)-
21-{4-[3,6-bis(diethylamino)pyridin-2-yl]piperazin-1-yl}-16-methylpregna-1,4,9(11)-triene-3,20-dione--hydrogen chloride (1/1)
DTXSID70911497
Q27280674
(8s,10s,13s,14s,16r,17s)-17-[2-[4-[3,6-bis(diethylamino)pyridin-2-yl]piperazin-1-yl]acetyl]-10,13,16-trimethyl-6,7,8,12,14,15,16,17-octahydrocyclopenta[a]phenanthren-3-one;hydrochloride
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (79)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (3.80)18.7374
1990's66 (83.54)18.2507
2000's8 (10.13)29.6817
2010's2 (2.53)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.47%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other79 (97.53%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]